Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Your genes may reveal hidden heart risks

NCT ID NCT01524549

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 14 times

Summary

This study looked at how certain gene variations affect the health of blood vessels in 178 healthy adults. Participants had an ultrasound and a short-acting medication to measure blood flow. The goal was to learn more about genetic risks for heart disease, not to provide treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

178 people

The number who actually took part.

Started

Mar 2012

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Genotype data from the EPR will be used to identify potential study participants@@@@@@

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Participant of the Environmental Polymorphisms Registry and current contact information available * Genotype information available for relevant CYP2J2 and EPHX2 polymorphisms, which indicates: * WT for EPHX2 K55R and WT for CYP2J2 7 * WT for EPHX2 K55R and heterozygous for CYP2J2 7 * WT for EPHX2 K55R and homozygous for CYP2J2 7 * WT for CYP2J2 7 and heterozygous for EPHX2 K55R (N=30) * WT for CYP2J2 7 and homozygous for EPHX2 K55R (N=30) * Age 18-70 years * Willing and able to provide informed consent * Able to comply with all protocol procedures EXCLUSION CRITERIA: * Currently pregnant or breast feeding * Hospitalized for a cardiovascular disease or stroke event within the previous 3 months * Current use of long-acting nitrates (e.g., isosorbide mononitrate, isosorbide dinitrate) * Current use of medications taken for hypertension. * For participants with current daily or chronic use of NSAIDs; unable or unwilling to refrain from taking NSAIDs for 7 days prior to enrollment visit. * Current use of insulin for Type I Diabetes * Presence of a pacemaker or implanted cardioverter-defibrillator * Presence of an irregular heart rhythm (atrial fibrillation) at the study visit * Current resting heart rate \<40 or \>125 beats per minute * Current systolic blood pressure \<90 or \>180 mmHg, or diastolic blood pressure \>110 mmHg * Skin sensitivity precluding use of ECG electrodes * History of hypersensitivity to nitroglycerin or other nitrates or nitrites * History of infection within the preceding 1 week or temperature \>38 degrees C * Unwilling or unable to: * Fast (including alcohol and caffeine-containing products) and discontinue tobacco use for 12 hours prior to Visit 1 * Withhold all prescribed and over-the-counter medications and supplements the morning of Visit 1, until after the visit is completed * Refrain from taking the following, as needed, medications for 7 days prior to Visit 1: * Vasoactive agents, such as decongestants (e.g., pseudoephedrine) * Recreational drugs such as marijuana, cocaine, and amphetamines * Anti-inflammatory agents (NSAIDs), such as ibuprofen, naproxen or aspirin * Sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) Exclusion of Pregnant and Breast Feeding Women: Any woman who is pregnant or breast feeding will be excluded from this study because nitroglycerin, administered as part of the study, is category C, and it is unknown whether nitroglycerin can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity; it is also unknown whether nitroglycerin is excreted in human milk. Also, hormonal changes associated with pregnancy can significantly influence the proposed measures of endothelial function. Females will have a urine pregnancy test prior to undergoing study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NIEHS Clinical Research Unit (CRU)

    Research Triangle Park, North Carolina, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.